OBJECTIVE: Since the beginning of the transcatheter aortic valve implantation (TAVI) era, many prosthetic valves have entered clinical practice. TAVI prostheses differ regarding stent design and some may potentially interfere with diagnostic or interventional catheters. The aim of our analysis was to evaluate the feasibility of coronary angiography (CA) or percutaneous coronary intervention (PCI) in patients with prior TAVI. METHODS: From 2011 to 2014, 1,000 patients were treated by TAVI at our center using eight different valve prostheses (Symetis ACURATE TA and ACURATE TF; Medtronic CoreValve and Engager; JenaValve, SJM Portico; Edwards Lifesciences SAPIEN and SAPIEN XT). In this analysis, all patients were included who underwent either CA or PCI after TAVI. CA or PCI were rated as fully feasible when coronary ostia could be fully intubated, partially feasible when coronary arteries could be displayed only unselectively or unfeasible when coronary arteries could not be displayed. RESULTS: A total of 35 patients underwent CA/PCI after TAVI at our hospital. In all patients with valves implanted in a subcoronary position (SAPIEN n = 19; JenaValve n = 1), selective intubation was feasible using standard catheters. Out of 15 patients with valve types that are placed over the coronary ostia (CoreValve n = 10, ACURATE n = 4, Portico n = 1), selective intubation of coronary arteries was not possible in 9 cases, even with the use of different diagnostic catheters. Full accessibility was possible only in 3 cases. In 2 cases, display of the right CA was only feasible using unselective aortography. In 1 case, coronary arteries could not be displayed at all immediately after a valve-in-valve procedure. CONCLUSION: CA or PCI after TAVI is usually feasible. Devices that are placed in a partially supracoronary position, however, can interfere with diagnostic or guiding catheters and impede straightforward intervention, especially when the prosthesis is not implanted in the correct position.
OBJECTIVE: Since the beginning of the transcatheter aortic valve implantation (TAVI) era, many prosthetic valves have entered clinical practice. TAVI prostheses differ regarding stent design and some may potentially interfere with diagnostic or interventional catheters. The aim of our analysis was to evaluate the feasibility of coronary angiography (CA) or percutaneous coronary intervention (PCI) in patients with prior TAVI. METHODS: From 2011 to 2014, 1,000 patients were treated by TAVI at our center using eight different valve prostheses (Symetis ACURATE TA and ACURATE TF; Medtronic CoreValve and Engager; JenaValve, SJM Portico; Edwards Lifesciences SAPIEN and SAPIEN XT). In this analysis, all patients were included who underwent either CA or PCI after TAVI. CA or PCI were rated as fully feasible when coronary ostia could be fully intubated, partially feasible when coronary arteries could be displayed only unselectively or unfeasible when coronary arteries could not be displayed. RESULTS: A total of 35 patients underwent CA/PCI after TAVI at our hospital. In all patients with valves implanted in a subcoronary position (SAPIEN n = 19; JenaValve n = 1), selective intubation was feasible using standard catheters. Out of 15 patients with valve types that are placed over the coronary ostia (CoreValve n = 10, ACURATE n = 4, Portico n = 1), selective intubation of coronary arteries was not possible in 9 cases, even with the use of different diagnostic catheters. Full accessibility was possible only in 3 cases. In 2 cases, display of the right CA was only feasible using unselective aortography. In 1 case, coronary arteries could not be displayed at all immediately after a valve-in-valve procedure. CONCLUSION: CA or PCI after TAVI is usually feasible. Devices that are placed in a partially supracoronary position, however, can interfere with diagnostic or guiding catheters and impede straightforward intervention, especially when the prosthesis is not implanted in the correct position.
Authors: Peter Wenaweser; Thomas Pilgrim; Enio Guerios; Stefan Stortecky; Christoph Huber; Ahmed A Khattab; Alexander Kadner; Lutz Buellesfeld; Steffen Gloekler; Bernhard Meier; Thierry Carrel; Stephan Windecker Journal: EuroIntervention Date: 2011-09 Impact factor: 6.534
Authors: Todd M Dewey; David L Brown; Morley A Herbert; Dan Culica; Craig R Smith; Martin B Leon; Lars G Svensson; Murat Tuzcu; John G Webb; Alain Cribier; Michael J Mack Journal: Ann Thorac Surg Date: 2010-03 Impact factor: 4.330
Authors: Anne-Kathrin Funkat; Andreas Beckmann; Jana Lewandowski; Michael Frie; Wolfgang Schiller; Markus Ernst; Khosro Hekmat; Jan F Gummert; Friedrich-Wilhelm Mohr Journal: Thorac Cardiovasc Surg Date: 2012-09-03 Impact factor: 1.827
Authors: Miralem Pasic; Stephan Dreysse; Axel Unbehaun; Semih Buz; Thorsten Drews; Christoph Klein; Giuseppe D'Ancona; Roland Hetzer Journal: Interact Cardiovasc Thorac Surg Date: 2012-01-09
Authors: Lenard Conradi; Moritz Seiffert; Olaf Franzen; Stephan Baldus; Johannes Schirmer; Thomas Meinertz; Hermann Reichenspurner; Hendrik Treede Journal: Clin Res Cardiol Date: 2010-10-21 Impact factor: 5.460
Authors: Christian W Hamm; Helge Möllmann; David Holzhey; Andreas Beckmann; Christof Veit; Hans-Reiner Figulla; J Cremer; Karl-Heinz Kuck; Rüdiger Lange; Ralf Zahn; Stefan Sack; Gerhard Schuler; Thomas Walther; Friedhelm Beyersdorf; Michael Böhm; Gerd Heusch; Anne-Kathrin Funkat; Thomas Meinertz; Till Neumann; Konstantinos Papoutsis; Steffen Schneider; Armin Welz; Friedrich W Mohr Journal: Eur Heart J Date: 2013-09-10 Impact factor: 29.983
Authors: Maria von Stumm; Tatjana Sequeira-Gross; Johannes Petersen; Shiho Naito; Lisa Müller; Christoph Sinning; Evaldas Girdauskas Journal: Cardiovasc Diagn Ther Date: 2021-04
Authors: Brandon M Jones; Amar Krishnaswamy; E Murat Tuzcu; Stephanie Mick; Wael A Jaber; Lars G Svensson; Samir R Kapadia Journal: Nat Rev Cardiol Date: 2017-07-06 Impact factor: 32.419